Incyte bags Opzelura EC approval for treatment of non-segmental vitiligo

Incyte bags Opzelura EC approval for treatment of non-segmental vitiligo

Incyte has secured marketing authorization for Opzelura (ruxolitinib) cream 15mg/g from the European Commission (EC) for non-segmental vitiligo with facial involvement in adults and adolescents, aged 12 years and above. Opzelura is a cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib. It has been approved in the European Union (EU) to offer support for repigmentation […]

US biopharma company Incyte bags Opzelura FDA approval for vitiligo

US biopharma company Incyte bags Opzelura FDA approval for vitiligo

Opzelura FDA approval for vitiligo : Incyte has secured approval for Opzelura (ruxolitinib) cream 1.5% from the US Food and Drug Administration (FDA) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients, aged 12 and older. Opzelura is a cream formulation of ruxolitinib, which selectively inhibits JAK1/JAK2. Opzelura FDA approval for vitiligo […]